New Treatment for Stomach Cancer Patients Shows Promise

OncologyONCOLOGY Vol 16 No 1
Volume 16
Issue 1

The results of a 10-year study of a three-pronged treatment (surgical resection followed by chemotherapy and radiotherapy) for adenocarcinoma of the stomach showed that patients who underwent both surgical resection and postoperative

The results of a 10-year study of a three-prongedtreatment (surgical resection followed by chemotherapy and radiotherapy) foradenocarcinoma of the stomach showed that patients who underwent both surgicalresection and postoperative chemoradiotherapy had a significantly improvedsurvival rate. Past studies found that chemoradiotherapy alone after surgery didnot increase survival. More extensive surgery has also been investigated and hasfailed to improve outcome. However, the three-pronged approach produced asignificant decrease in relapse and increase in survival rates.

Stephen R. Smalley, MD, of Therapeutic Radiologists Inc, in Kansas City,originally developed the study in 1987. Because the radiotherapy wasexperimental, all radiation oncologists treating patients in this study wererequired to get his approval of the radiation planned for each patient prior totherapy.

"The most promising news is that this approach leads to significantimprovement in both disease-free and overall survival among thesepatients," said Dr. Smalley. "This research changes the standardprotocol for the treatment of most patients with completely resected stomachcancer."

Survival and Relapse Rate Improve

The study enrolled 556 patients following curative surgery. Participants werethen randomized to receive no further treatment or both chemotherapy andradiotherapy. Survival was substantially higher in the group that receivedchemoradiotherapy after surgery. The median survival rate in the surgery-onlygroup was 27 months. Among patients who underwent both chemotherapy andradiotherapy, the median survival was 36 months and the relapse-free period wasalso higher. "The median time in which patients had no relapse was 30months in the chemoradiotherapy group, compared to 19 months in the surgery-onlygroup," said Dr. Smiley.

However, the results of this study, reported in the New England Journal ofMedicine (345:725-730, 2001), apply only to patients in whom all visible signsof cancer can be removed surgically. The authors of the study emphasized thatproper nutrition is also a significant part of treatment.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content